Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.
Subject: Parkinson's Disease - PUBLISHED VIA Neurobiology of Disease
Author(s):
Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J
View Source >>
(Price: $40)
Related Studies:
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial.
Published via Journal of Psychopharmacology
Prospects for cannabinoid therapies in basal ganglia disorders.
Published via British Journal of Pharmacology
Cannabidiol for the treatment of psychosis in Parkinson’s disease.
Published via Journal of Psychopharmacology
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series.
Published via Journal of Clinical Pharmacy and Therapeutics
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties.
Published via Brain Research